Drug Profile
SHR 0410
Alternative Names: SHR-0410Latest Information Update: 12 Sep 2022
Price :
$50
*
At a glance
- Originator Atridia
- Class Analgesics; Antipruritics
- Mechanism of Action Opioid kappa receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Postoperative pain
- Phase I Acute pain; Pruritus
Most Recent Events
- 09 Aug 2022 Jiangsu HengRui Medicine initiates a phase II trial for Postoperative pain in China (IV) (NCT05394402)
- 22 Jul 2022 Jiangsu HengRui Medicine plans a phase II trial for Postoperative pain(Combination therapy) (IV,Injection) in August 2022 (NCT05470049)
- 14 Jul 2022 Jiangsu HengRui Medicine plans a phase III trial for Postoperative pain (Injection) (NCT05459220)